The Novel Cyclin-dependent Kinase Inhibitor Dinaciclib (SCH727965) Promotes Apoptosis and Abrogates Microenvironmental Cytokine Protection in Chronic Lymphocytic Leukemia Cells

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2012 Jul 14

PMID 22791353

Citations 43

Authors

A J Johnson

Y-Y Yeh

L L Smith

A J Wagner

J Hessler

S Gupta

J Flynn

J Jones

X Zhang

R Bannerji

M R Grever

J C Byrd

Affiliations

Soon will be listed here.

Citing Articles

Dinaciclib Interrupts Cell Cycle and Induces Apoptosis in Oral Squamous Cell Carcinoma: Mechanistic Insights and Therapeutic Potential.

Oner M, Cheng Y, Soong S, Cheng P, Wang Y, Yang S Int J Mol Sci. 2025; 26(5).

PMID: 40076816 PMC: 11900514. DOI: 10.3390/ijms26052197.

CDK9 inhibition as an effective therapy for small cell lung cancer.

Valdez Capuccino L, Kleitke T, Szokol B, Svajda L, Martin F, Bonechi F Cell Death Dis. 2024; 15(5):345.

PMID: 38769311 PMC: 11106072. DOI: 10.1038/s41419-024-06724-4.

PIK Your Poison: The Effects of Combining PI3K and CDK Inhibitors against Metastatic Cutaneous Squamous Cell Carcinoma In Vitro.

Perry J, Genenger B, Thind A, Ashford B, Ranson M Cancers (Basel). 2024; 16(2).

PMID: 38254859 PMC: 10814950. DOI: 10.3390/cancers16020370.

Super-Enhancer-Associated nine-gene prognostic score model for prediction of survival in chronic lymphocytic leukemia patients.

Liang X, Meng Y, Li C, Liu L, Wang Y, Pu L Front Genet. 2022; 13:1001364.

PMID: 36186463 PMC: 9521409. DOI: 10.3389/fgene.2022.1001364.

Synthesis and Biological Evaluation of Imadazo[1,2-]pyrazines as Anticancer and Antiviral Agents through Inhibition of CDK9 and Human Coronavirus.

Alsfouk A, Alshibl H, Alsfouk B, Altwaijry N, Al-Abdullah E Pharmaceuticals (Basel). 2022; 15(7).

PMID: 35890157 PMC: 9319549. DOI: 10.3390/ph15070859.

References

Woyach J, Lozanski G, Ruppert A, Lozanski A, Blum K, Jones J . Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features. Leukemia. 2012; 26(6):1442-4. PMC: 3675648. DOI: 10.1038/leu.2011.375. View

Hussain S, Lucas D, Johnson A, Lin T, Bakaletz A, Dang V . Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. Blood. 2008; 111(6):3190-9. PMC: 2265456. DOI: 10.1182/blood-2007-10-115733. View

Gilboa N, Durante D, Guggenheim S, Lacher J, Holman R, Schorr W . Immune deposit nephritis and single-component cryoglobulinemia associated with chronic lymphocytic leukemia. Evidence for a role of circulating IgG-anti-IgG immune complexes in the pathogenesis of the renal lesion. Nephron. 1979; 24(5):223-31. DOI: 10.1159/000181721. View

Sadhu C, Dick K, Tino W, Staunton D . Selective role of PI3K delta in neutrophil inflammatory responses. Biochem Biophys Res Commun. 2003; 308(4):764-9. DOI: 10.1016/s0006-291x(03)01480-3. View

Lin T, Ruppert A, Johnson A, Fischer B, Heerema N, Andritsos L . Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol. 2009; 27(35):6012-8. PMC: 2793044. DOI: 10.1200/JCO.2009.22.6944. View

Konig A, Schwartz G, Mohammad R, Al-Katib A, GABRILOVE J . The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood. 1997; 90(11):4307-12. View

Grever M, Lucas D, Johnson A, Byrd J . Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. Best Pract Res Clin Haematol. 2007; 20(3):545-56. DOI: 10.1016/j.beha.2007.03.005. View

Byrd J, Shinn C, Waselenko J, Fuchs E, Lehman T, Nguyen P . Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood. 1998; 92(10):3804-16. View

Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D . Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther. 2010; 9(8):2344-53. DOI: 10.1158/1535-7163.MCT-10-0324. View

10.

Niedermeier M, Hennessy B, Knight Z, Henneberg M, Hu J, Kurtova A . Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood. 2009; 113(22):5549-57. PMC: 4580965. DOI: 10.1182/blood-2008-06-165068. View

11.

Herman S, Gordon A, Hertlein E, Ramanunni A, Zhang X, Jaglowski S . Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011; 117(23):6287-96. PMC: 3122947. DOI: 10.1182/blood-2011-01-328484. View

12.

Phelps M, Lin T, Johnson A, Hurh E, Rozewski D, Farley K . Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood. 2008; 113(12):2637-45. PMC: 2661854. DOI: 10.1182/blood-2008-07-168583. View

13.

Paruch K, Dwyer M, Alvarez C, Brown C, Chan T, Doll R . Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases. ACS Med Chem Lett. 2014; 1(5):204-8. PMC: 4007794. DOI: 10.1021/ml100051d. View

14.

Kitada S, Zapata J, Andreeff M, Reed J . Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood. 2000; 96(2):393-7. View

15.

Hallek M, Cheson B, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111(12):5446-56. PMC: 2972576. DOI: 10.1182/blood-2007-06-093906. View